Ignite Creation Date:
2025-12-25 @ 5:03 AM
Ignite Modification Date:
2026-03-05 @ 2:20 PM
Study NCT ID:
NCT05493618
Status:
WITHDRAWN
Last Update Posted:
2023-01-27
First Post:
2022-08-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.
Sponsor:
Hackensack Meridian Health
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Myeloma, Refractory | View |
Keywords: